Herzog TJ, Liao JB, Finkelstein K, Willmott L, et al. An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol 2025;194:145-152.
PMID: 40221173